Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation

Abstract

Background—Anticoagulation with adjusted dose warfarin is a well-accepted treatment for the prevention of recurrent stroke in patients with atrial fibrillation. Meanwhile, using bridging therapy with heparin
or heparinoids before warfarin for initiation of anticoagulation is a matter of debate. We compared safety,
efficacy, and tolerability of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) as a
bridging method in patients with recent ischemic stroke due to atrial fibrillation.
Method—This study was a randomized single-blind controlled trial in patients with acute ischemic stroke
due to atrial fibrillation who were eligible for receiving warfarin and were randomly treated with 60 milligrams (mg) of LMWH (enoxaparin) subcutaneously every 12 h, or 1000 units/h of continuous intravenous
heparin. The primary efficacy endpoints were recurrence of new ischemic stroke, myocardial infarction
and/or death. The primary safety endpoint was central nervous system and/or systemic bleeding.
Results—Seventy-four subjects were recruited. Baseline demographic and clinical characteristics of two
groups were matched. Composite endpoint outcome of new ischemic stroke, myocardial infarction, and/or
death in follow-up period was seen in 10 subjects (27.03%) in UFH group and in four subjects (10.81%) in
LMWH group (p value: 0.136). All hemorrhages and symptomatic central nervous system (CNS) hemorrhages in follow-up period were in 7 (18.9%) and 4 (10.8%) patients in UFH group, in 5 (13.5%), and 3
(8.1%) patients in LMWH group (p values: 0.754 and 0.751), respectively. Drop out and major adverseeffects such as heparin-induced thrombocytopenia and drug hypersensitivity were not seen in any patient.
Conclusion—Enoxaparin can be a safe and efficient alternative for UFH as bridging therapy